文献速递消化系统肿瘤

270种血浆蛋白标志物多重定量用于结直肠癌早期检测

Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.
PubMed 文献 · Eur J Cancer · 2020-01-21

外部验证AUC分别为0.79(95%CI 0.70-0.86)、0.79(95%CI 0.66-0.89)和0.80(95%CI 0.70-0.89);三标志物早期算法检测进展期腺瘤的AUC为0.65(95%CI 0.56-0.73)。作者认为尚不能与现有粪便检测竞争,但相关蛋白可能有助于开发血液早检方法。

要点

  • 全期、早期、晚期结直肠癌签名外部验证AUC分别为0.79、0.79、0.80。
  • 三标志物早期算法检测进展期腺瘤的AUC为0.65(95%CI 0.56-0.73)。
  • 作者指出该标志物尚不能与现有粪便检测竞争,需进一步开发。

核心结论

  • 270种血浆蛋白标志物可构建结直肠癌早期检测签名,但尚不能与现有粪便检测竞争。

研究设计与样本

  • 两阶段设计,用液相色谱-多重反应监测-质谱检测血浆270种蛋白标志物。
  • 发现集为100例新诊断结直肠癌和100例年龄性别匹配、结肠镜无肿瘤对照。
  • 外部验证集为独立筛查结肠镜人群,含56例结直肠癌、99例进展期腺瘤和99例无肿瘤对照。

主要发现

  • 发现集获得全期、早期、晚期结直肠癌的5、3、8蛋白标志物签名。
  • 外部验证全期、早期、晚期结直肠癌AUC分别为0.79(95%CI 0.70-0.86)、0.79(95%CI 0.66-0.89)和0.80(95%CI 0.70-0.89)。
  • 三标志物早期算法检测进展期腺瘤的AUC为0.65(95%CI 0.56-0.73)。

临床怎么用

  • 该血浆蛋白签名目前不优于粪便检测,暂不支持直接用于人群筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blood-based protein biomarker signatures might be an alternative or supplement to existing methods for early detection of colorectal cancer (CRC) for population-based screening. The objective of this study was to derive a protein biomarker signature for early detection of CRC and its precursor advanced adenoma (AA). In a two-stage design, 270 protein markers were measured by liquid chromatography/multiple reaction monitoring/mass spectrometry in plasma samples of discovery and validation sets. In the discovery set consisting of 100 newly diagnosed CRC cases and 100 age- and sex-matched controls free of neoplasm at screening colonoscopy, the algorithms predicting the presence of early- or late-stage CRC were derived by Lasso regression and .632 + bootstrap. The prediction algorithms were then externally validated in an independent validation set consisting of participants of screening colonoscopy including 56 participants with CRC, 99 with AA and 99 controls without any colorectal neoplasms. Three different signatures for all-, early- and late-stage CRC consisting of five-, three- and eight-protein markers were obtained in the discovery set with areas under the curves (AUCs) after .632 + bootstrap adjustment of 0.85, 0.83 and 0.96, respectively. External validation in the representative screening population yielded AUCs of 0.79 (95% CI, 0.70-0.86), 0.79 (95% CI, 0.66-0.89) and 0.80 (95% CI, 0.70-0.89) for all-, early- and late-stage CRCs, respectively. The three-marker early-stage algorithm yielded an AUC of 0.65 (95% CI, 0.56-0.73) for detection of AA in the validation set. Although not yet competitive with available stool-based tests for CRC early detection, the identified proteins may contribute to the development of powerful blood-based tests for early detection of CRC and its precursors AAs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bhardwaj M, Weigl K, Tikk K, et al. Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer. Eur J Cancer. 2020. PMID: 31972396. doi:10.1016/j.ejca.2019.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。